 | Up a level |
Number of items: 1.
Schmid, P., Salvador Bofill, J., Bermejo, B., Phillips, M., Wheatley, D., Neus, F., Schem, C., Stradella, A., Mele, M., Cortes Salgado, A., Quiroga, V., Anton Torres, A., Llombart Cussac, A., Zamora, E., Viale, G., Kuemmel, S., Prendergast, A., Mousa, K., Gluz, O. and Cortes, J. (2021). BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer. Ann. Oncol., 32. S. S411 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041